Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2717121 | 0.87 | EPHX2 (1.00) | EPHX2EPHX1 | |
| SCHEMBL5571085 | 0.86 | EPHX2 (1.00) | EPHX2EPHX1 | |
| SCHEMBL14997505 | 0.86 | EPHX2 (0.75) | EPHX2EPHX1 | |
| SCHEMBL3346010 | 0.86 | EPHX2 (1.00) | EPHX2EPHX1 | |
| SCHEMBL4997818 | 0.85 | EPHX2 (0.79) | EPHX2EPHX1 | |
| SCHEMBL3966721 | 0.85 | EPHX2 (0.73) | EPHX2EPHX1 | |
| SCHEMBL2716707 | 0.85 | EPHX2 (1.00) | EPHX2EPHX1 | |
| SCHEMBL2719283 | 0.84 | EPHX2 (1.00) | EPHX2EPHX1 | |
| SCHEMBL2717167 | 0.82 | EPHX2 (1.00) | EPHX2 | |
| SCHEMBL5571465 | 0.82 | EPHX2 (1.00) | EPHX2EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010053829-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS FOR TREATMENT OF METABOLIC SYNDROME AND RELATED DISORDERS | ARETE THERAPEUTICS, INC. (US) | 2010-05-14 | — | — | WO | claimed |
| US-20090270452-A1 | USE OF SOLUBLE EPOXIDE HYDROLASE INHIBITORS IN THE TREATMENT OF SMOOTH MUSCLE DISORDERS | ARETE THERAPEUTICS, INC. | 2009-10-29 | — | — | US | claimed |
| WO-2009129501-A1 | USE OF SOLUBLE EPOXIDE HYDROLASE INHIBITORS IN THE TREATMENT OF SMOOTH MUSCLE DISORDERS | ARETE THERAPEUTICS, INC. (US) | 2009-10-22 | — | — | WO | claimed |
| US-20090247521-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS FOR THE TREATMENT OF ENDOTHELIAL DYSFUNCTION | ARETE THERAPEUTICS, INC. | 2009-10-01 | — | — | US | claimed |
| US-20090197916-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS FOR TREATMENT OF METABOLIC SYNDROME AND RELATED DISORDERS | ARETE THERAPEUTICS, INC | 2009-08-06 | — | — | US | claimed |
| WO-2009086426-A2 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS FOR THE TREATMENT OF ENDOTHELIAL DYSFUNCTION | ARETE THERAPEUTICS, INC. (US) | 2009-07-09 | — | — | WO | claimed |
| US-20080221100-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | ARETE THERAPEUTICS, INC. | 2008-09-11 | — | — | US | claimed |
| US-10758511-B2 | Stable analogs of CYP450 lipid metabolites and inhibitors of soluble epoxide hydrolase | MASSACHUSETTS EYE AND EAR INFIRMARY (US) | 2020-09-01 | — | — | US | disclosed |
| EP-2528604-B1 | ACYL PIPERIDINE INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE | UNIV CALIFORNIA (US) | 2017-11-22 | — | — | EP | disclosed |
| EP-2528604-B1 | ACYL PIPERIDINE INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE | UNIV CALIFORNIA (US) | 2017-11-22 | — | — | EP | disclosed |
| US-20160200683-A1 | ACYL PIPERIDINE INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE | UNIV CALIFORNIA (US) | 2016-07-14 | — | — | US | disclosed |
| US-20160200683-A1 | ACYL PIPERIDINE INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE | UNIV CALIFORNIA (US) | 2016-07-14 | — | — | US | disclosed |
| US-9296693-B2 | Acyl piperidine inhibitors of soluble epoxide hydrolase | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-03-29 | — | — | US | disclosed |
| US-20090197916-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS FOR TREATMENT OF METABOLIC SYNDROME AND RELATED DISORDERS | ARETE THERAPEUTICS, INC | 2009-08-06 | — | — | US | disclosed |
| WO-2009086426-A2 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS FOR THE TREATMENT OF ENDOTHELIAL DYSFUNCTION | ARETE THERAPEUTICS, INC. (US) | 2009-07-09 | — | — | WO | disclosed |
| WO-2009086426-A2 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS FOR THE TREATMENT OF ENDOTHELIAL DYSFUNCTION | ARETE THERAPEUTICS, INC. (US) | 2009-07-09 | — | — | WO | disclosed |
| US-20080221100-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | ARETE THERAPEUTICS, INC. | 2008-09-11 | — | — | US | disclosed |
| US-20080221100-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | ARETE THERAPEUTICS, INC. | 2008-09-11 | — | — | US | disclosed |
| US-20080221100-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | ARETE THERAPEUTICS, INC. | 2008-09-11 | — | — | US | disclosed |
| WO-2008051873-A2 | PHENYLUREA COMPOUNDS AS SOLUBLE EPOXIDE HYDROLASE INHIBITORS | ARETE THERAPEUTICS, INC. (US) | 2008-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247521-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS FOR THE TREATMENT OF ENDOTHELIAL DYSFUNCTION | EPHX1, ECE1, LIPG | EPHX2 5/4885EPHX1 1/4885 |
| US-20090270452-A1 | USE OF SOLUBLE EPOXIDE HYDROLASE INHIBITORS IN THE TREATMENT OF SMOOTH MUSCLE DISORDERS | EPHX1, PTGIS, PDE3A | EPHX2 6/4885EPHX1 1/4885 |
| US-10758511-B2 | Stable analogs of CYP450 lipid metabolites and inhibitors of soluble epoxide hydrolase | EPHX1, EPHX2, LIPG | EPHX2 2/4885EPHX1 1/4885 |
| US-20080221100-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | EPHX1, EPHX2, NCEH1 | EPHX2 2/4885EPHX1 1/4885 |
| US-20160200683-A1 | ACYL PIPERIDINE INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE | EPHX1, FAAH, FAAH2 | EPHX2 4/4885EPHX1 1/4885 |
| US-20090197916-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS FOR TREATMENT OF METABOLIC SYNDROME AND RELATED DISORDERS | EPHX1, NCEH1, PNLIP | EPHX2 6/4885EPHX1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.